| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.99▲ | 0.99▲ | 0.99▲ | 1.00▼ | 1.01▼ |
| MA10 | 0.99▼ | 0.99▼ | 0.99▼ | 0.99▼ | 0.99▼ |
| MA20 | 1.03▼ | 1.03▼ | 1.02▼ | 0.99▼ | 1.03▼ |
| MA50 | 1.02▼ | 1.03▼ | 1.01▼ | 0.97▼ | 1.11▼ |
| MA100 | 1.03▼ | 1.02▼ | 0.99▲ | 1.03▼ | N/A |
| MA200 | 1.01▼ | 0.98▲ | 1.04▼ | 1.03▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.006▼ | -0.005▼ | -0.005▼ | -0.001▼ | 0.005▲ |
| RSI | 44.470▼ | 45.541▼ | 47.233▼ | 46.888▼ | 46.980▼ |
| STOCH | 14.317▼ | 14.317▼ | 14.317▼ | 58.329 | 52.345 |
| WILL %R | -93.085▼ | -93.085▼ | -93.085▼ | -55.000 | -55.769 |
| CCI | -43.236 | -43.275 | -43.515 | -58.988 | 14.278 |
| RSI | $ESLA RSI(14) Crossed Below 50 | Set Alert |
| ▼ MACD | $ESLA MACD(12,26,9) Crossed Below Zero | Set Alert |
| ▼ MACD | $ESLA MACD(12,26,9) Crossed Below Signal Line | Set Alert |
| MA | $ESLA Price Crossed Below MA(50) | Set Alert |
| MA | $ESLA Price Crossed Below MA(13) | Set Alert |
| MA | $ESLA Price Crossed Below MA(7) | Set Alert |
| ▼ GAP | $ESLA Open Gap Down %5 | Set Alert |
| ▼ GAP | $ESLA Open Gap Down %3 | Set Alert |
| ▼ GAP | $ESLA Open Gap Down %2 | Set Alert |
| CDL | $ESLA Doji Candlestick Pattern Detected | Set Alert |
|
Thursday, June 05, 2025 09:55 AM
Estrella Immunopharma Inc. (NASDAQ:ESLA) announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial. The trial is evaluating EB103, which is a ...
|
|
Tuesday, June 03, 2025 05:00 AM
Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and ...
|
|
Thursday, May 29, 2025 08:15 PM
Estrella Immunopharma, Inc. (NASDAQ:ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, dosing the first patient in the second cohort of its dose escalation study for ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/06/25 | 0.9583 | 0.99 | 0.955 | 0.96 | 18,059 |
| 12/06/25 | 0.9917 | 1.0498 | 0.9601 | 1.01 | 27,463 |
| 11/06/25 | 0.97 | 1.0599 | 0.97 | 0.9962 | 6,568 |
| 09/06/25 | 1.03 | 1.04 | 0.9365 | 0.9886 | 69,545 |
| 06/06/25 | 1.10 | 1.13 | 0.9942 | 1.0651 | 69,958 |
| 05/06/25 | 0.9603 | 1.075 | 0.9201 | 1.06 | 111,857 |
| 04/06/25 | 0.848 | 1.00 | 0.83 | 0.99 | 237,500 |
| 03/06/25 | 1.08 | 1.18 | 0.78 | 0.8342 | 9,516,120 |
| 02/06/25 | 0.97 | 0.9701 | 0.9585 | 0.97 | 4,093 |
| 30/05/25 | 0.97 | 1.0197 | 0.97 | 1.0096 | 12,386 |
|
|
||||
|
|
||||
|
|